Somatomedin inhibitors from diabetic rat serum alter growth and development of mouse embryos in culture

T. W. Sadler, L. S. Phillips, Wayne E Balkan, S. Goldstein

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Offspring of diabetic humans and laboratory animals have been shown to have a higher incidence of congenital malformations with attendant growth retardation. These defects have been attributed to alterations in the intrauterine environment and specifically to changes in maternal serum factors, e.g., glucose and ketone bodies. Our investigation examines the potential teratogenicity of a low-molecular-weight (940) serum fraction with demonstrated somatomedin inhibitory activity isolated by column chromatography from streptozocin-induced diabetic rats. Mouse embryos were exposed to control or the inhibitor fraction at concentrations of 0.25-0.6% vol/vol (0.9-3.0 μg protein/ml culture medium) in whole embryo culture and evaluated for the presence of malformations and growth retardation. Embryos exposed to inhibitor during the period of neurulation (3-5 somites) exhibited neural tube and craniofacial defects, whereas those exposed during early limb bud stages (18-19 somites) exhibited abnormalities of the forebrain and face. In addition, both stages were growth retarded. Control fractions produced no abnormalities. These results demonstrate a potential role for somatomedin inhibitors in diabetic embryopathy and suggest that factors other than hyperglycemia and hyperketonemia may contribute to the higher incidence of malformations among infants of diabetic mothers.

Original languageEnglish (US)
Pages (from-to)861-865
Number of pages5
JournalDiabetes
Volume35
Issue number8
StatePublished - 1986
Externally publishedYes

Fingerprint

Growth and Development
Somites
Embryonic Structures
Growth
Serum
Mothers
Neurulation
Fetal Diseases
Limb Buds
Ketone Bodies
Neural Tube Defects
Incidence
Laboratory Animals
Somatomedins
Streptozocin
Prosencephalon
Hyperglycemia
Culture Media
Chromatography
Molecular Weight

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Somatomedin inhibitors from diabetic rat serum alter growth and development of mouse embryos in culture. / Sadler, T. W.; Phillips, L. S.; Balkan, Wayne E; Goldstein, S.

In: Diabetes, Vol. 35, No. 8, 1986, p. 861-865.

Research output: Contribution to journalArticle

Sadler, T. W. ; Phillips, L. S. ; Balkan, Wayne E ; Goldstein, S. / Somatomedin inhibitors from diabetic rat serum alter growth and development of mouse embryos in culture. In: Diabetes. 1986 ; Vol. 35, No. 8. pp. 861-865.
@article{8908b7bcfefe4525b36d9b610a4fcf80,
title = "Somatomedin inhibitors from diabetic rat serum alter growth and development of mouse embryos in culture",
abstract = "Offspring of diabetic humans and laboratory animals have been shown to have a higher incidence of congenital malformations with attendant growth retardation. These defects have been attributed to alterations in the intrauterine environment and specifically to changes in maternal serum factors, e.g., glucose and ketone bodies. Our investigation examines the potential teratogenicity of a low-molecular-weight (940) serum fraction with demonstrated somatomedin inhibitory activity isolated by column chromatography from streptozocin-induced diabetic rats. Mouse embryos were exposed to control or the inhibitor fraction at concentrations of 0.25-0.6{\%} vol/vol (0.9-3.0 μg protein/ml culture medium) in whole embryo culture and evaluated for the presence of malformations and growth retardation. Embryos exposed to inhibitor during the period of neurulation (3-5 somites) exhibited neural tube and craniofacial defects, whereas those exposed during early limb bud stages (18-19 somites) exhibited abnormalities of the forebrain and face. In addition, both stages were growth retarded. Control fractions produced no abnormalities. These results demonstrate a potential role for somatomedin inhibitors in diabetic embryopathy and suggest that factors other than hyperglycemia and hyperketonemia may contribute to the higher incidence of malformations among infants of diabetic mothers.",
author = "Sadler, {T. W.} and Phillips, {L. S.} and Balkan, {Wayne E} and S. Goldstein",
year = "1986",
language = "English (US)",
volume = "35",
pages = "861--865",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "8",

}

TY - JOUR

T1 - Somatomedin inhibitors from diabetic rat serum alter growth and development of mouse embryos in culture

AU - Sadler, T. W.

AU - Phillips, L. S.

AU - Balkan, Wayne E

AU - Goldstein, S.

PY - 1986

Y1 - 1986

N2 - Offspring of diabetic humans and laboratory animals have been shown to have a higher incidence of congenital malformations with attendant growth retardation. These defects have been attributed to alterations in the intrauterine environment and specifically to changes in maternal serum factors, e.g., glucose and ketone bodies. Our investigation examines the potential teratogenicity of a low-molecular-weight (940) serum fraction with demonstrated somatomedin inhibitory activity isolated by column chromatography from streptozocin-induced diabetic rats. Mouse embryos were exposed to control or the inhibitor fraction at concentrations of 0.25-0.6% vol/vol (0.9-3.0 μg protein/ml culture medium) in whole embryo culture and evaluated for the presence of malformations and growth retardation. Embryos exposed to inhibitor during the period of neurulation (3-5 somites) exhibited neural tube and craniofacial defects, whereas those exposed during early limb bud stages (18-19 somites) exhibited abnormalities of the forebrain and face. In addition, both stages were growth retarded. Control fractions produced no abnormalities. These results demonstrate a potential role for somatomedin inhibitors in diabetic embryopathy and suggest that factors other than hyperglycemia and hyperketonemia may contribute to the higher incidence of malformations among infants of diabetic mothers.

AB - Offspring of diabetic humans and laboratory animals have been shown to have a higher incidence of congenital malformations with attendant growth retardation. These defects have been attributed to alterations in the intrauterine environment and specifically to changes in maternal serum factors, e.g., glucose and ketone bodies. Our investigation examines the potential teratogenicity of a low-molecular-weight (940) serum fraction with demonstrated somatomedin inhibitory activity isolated by column chromatography from streptozocin-induced diabetic rats. Mouse embryos were exposed to control or the inhibitor fraction at concentrations of 0.25-0.6% vol/vol (0.9-3.0 μg protein/ml culture medium) in whole embryo culture and evaluated for the presence of malformations and growth retardation. Embryos exposed to inhibitor during the period of neurulation (3-5 somites) exhibited neural tube and craniofacial defects, whereas those exposed during early limb bud stages (18-19 somites) exhibited abnormalities of the forebrain and face. In addition, both stages were growth retarded. Control fractions produced no abnormalities. These results demonstrate a potential role for somatomedin inhibitors in diabetic embryopathy and suggest that factors other than hyperglycemia and hyperketonemia may contribute to the higher incidence of malformations among infants of diabetic mothers.

UR - http://www.scopus.com/inward/record.url?scp=0022497381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022497381&partnerID=8YFLogxK

M3 - Article

C2 - 3732629

AN - SCOPUS:0022497381

VL - 35

SP - 861

EP - 865

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 8

ER -